NSE: SUNPHARMA · 30 October 2026
- SUN PHARMACEUTICAL IND L (SUNPHARMA) advanced by 0.95% on Thursday, closing at ₹1,777.70 against its previous close of ₹1,761.00. The stock opened at ₹1,770.90 and traded within a wide intraday range, touching a high of ₹1,852.70 and a low of ₹1,770.80.
- Sun Pharma announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. The approval expands the use of the IL-23 inhibitor beyond moderate-to-severe plaque psoriasis and is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies. The medication will be administered exclusively by healthcare providers.
- Trading volume was 3.40 times the 20-day average daily volume.
Why is Sun Pharmaceutical Ind L share price rising on 30 October 2026?
SUN PHARMACEUTICAL IND L (SUNPHARMA) advanced by 0.95% on Thursday, closing at ₹1,777.70 against its previous close of ₹1,761.00. The stock opened at ₹1,770.90 and traded within a wide intraday range, touching a high of ₹1,852.70 and a low of ₹1,770.80.
The broader market and sector backdrop provided a supportive environment for the pharmaceutical major. The benchmark Nifty index recorded a gain of 0.51%, while the Nifty Pharma sector index outperformed with a stronger move of 1.55%, reflecting broad-based buying interest across pharmaceutical equities. Over the short term, SUNPHARMA has posted a 5-day return of 1.70%, though its 20-day return stands at -2.14%, indicating recent consolidation prior to the session's uptick.
Company developments during the period included multiple corporate updates, notably the announcement of US FDA approval for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis, alongside the outcome of its board meeting concerning unaudited financial results and mandatory statutory auditor rotation. While these updates provide fundamental context regarding the company's expanding specialty portfolio and ongoing governance measures, market participants also weighed broader sector momentum during the trading session.
50.96 lakh shares traded by 30 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 14.98 lakh shares (3.40 times). The five-day average daily volume was 12.80 lakh shares. Separately, the NSE report for 29 October 2026 showed 6.59 lakh shares delivered, representing 59.46% of that day’s traded volume. The same report recorded 63,500 trades.
The stock moved higher in tandem with a strong outperformance in the Nifty Pharma sector and elevated trading volumes exceeding 3.4 times its 20-day average, alongside recent ongoing product regulatory updates.
Latest Company Developments
Sun Pharma announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. The approval expands the use of the IL-23 inhibitor beyond moderate-to-severe plaque psoriasis and is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies. The medication will be administered exclusively by healthcare providers.
This regulatory approval broadens the commercial addressable market for Sun Pharma's high-growth specialty dermatology and rheumatology portfolio in the United States.
Following the conclusion of the second consecutive five-year term of existing statutory auditors S R B C & CO LLP in accordance with mandatory rotation rules under the Companies Act, 2013, the board approved the appointment of Deloitte Haskins & Sells Chartered Accountants LLP. The appointment is for a five-year term starting from the conclusion of the 2026-27 annual general meeting until the 2031-32 AGM, subject to shareholder approval.
Ensures seamless regulatory compliance and continuity in financial oversight as per statutory governance norms.
The company completed the allotment of rated, listed, unsecured, redeemable non-convertible debentures aggregating to ₹7,816 crore on a private placement basis. This comprised Series A debentures of ₹2,003 crore carrying an 8.05% coupon and Series B debentures of ₹5,813 crore carrying an 8.20% coupon, after exercising a greenshoe option of ₹816 crore over a base issue size of ₹7,000 crore.
Demonstrates strong capital-raising capability at competitive coupon rates to support the company's financial structure.
a press release dated October 30, 2026, titled "ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis".
'Completion and Result of Postal Ballot dated 25 August 2026'.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.01% on 30 September 2026. This compares with 12.84% on 30 June 2026, a change of +0.17 percentage points.
The filing reported 51 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution and market uptake of ILUMYA following its U.S. approval for active psoriatic arthritis
- Performance trends in the global specialty medicines and US generic portfolio
- Cash volume and delivery percentage sustainability relative to the 20-day average volume baseline
- Quarterly financial performance updates and management commentary on operating margins
Other Dated Coverage
- Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Rising 0.74% | 22 October 2026 — 22 October 2026
- Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Falling 0.17% | 21 October 2026 — 21 October 2026
- Sun Pharma in Focus After CRISIL and ICRA Assign NCD Ratings | 15 October 2026 — 15 October 2026
More Sun Pharmaceutical Ind L news and dated analysis →
Frequently Asked Questions
What is the latest Sun Pharmaceutical Ind L company news?
Sun Pharma announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. The approval expands the use of the IL-23 inhibitor beyond moderate-to-severe plaque psoriasis and is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies. The medication will be administered exclusively by healthcare providers.
How strong was Sun Pharmaceutical Ind L’s trading volume?
50.96 lakh shares traded, 3.40 times the 20-day average daily volume. The price and volume data are dated 30 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.